Active pharmaceutical ingredient production will be the driving factor behind a predicted boom in the pharmaceutical contract manufacturing market, according to Visiongain.
Automated drug accountability systems are becoming “the norm” in clinical trials because they can improve compliance and cut working time drastically, according to Cenduit.
Regulatory professionals working for contract research organisations (CROs) in emerging markets could benefit from taking a test to bring them up to par with those in developed countries, according to RAPS.
Hospira has bought Orchid Chemicals and Pharmaceutical’s active pharmaceutical ingredient (API) facility in Aurangabad, India, to support its expanding antibiotic business.
GlaxoSmithKline (GSK) and AstraZeneca have been attracted by NHS efforts to work with sponsors and CROs outside the UK according to Government investment group, UK Trade and Investment.
Health economics and outcomes research teams must have a greater influence over clinical trial design if pharma firms are to achieve reimbursement goals, according to Cutting Edge Information.
CROs conducting bioequivalence and bioavailability (BE/BA) studies for generics firms will have to log details of their sites with the US FDA under new ‘self-identification’ rules.
Comprehend Systems recently made its data analytics, visualisations and reports software available from the cloud. CEO Rick Morrison spoke with Outsourcing-Pharma.com about the firm’s reasoning, and why no rockets were needed in the launch.
The proposed changes to European clinical trial regulations accepted by the European Commission (EC) in July will put Europe on an equal playing field, according to Clinipace’s Andrea Schiefer.
A new hydrogel which can provide a sustained drug release of up to six months could cut diabetes dosage down from 365 injection per year to just two, according to researchers.
Theorem and Gallus say their new biologics manufacturing partnership is aimed at giving a “leg up” to drugsmakers in emerging markets looking to market products in the US.
Icon has boosted its Phase I translational medicine services in Manchester, UK, in preparation for what it believes will be a boom in the drug development area.
US biosecurity experts are calling on industry and the Government to “get a handle” on the supply chain for drugs used in times of pandemic or bio attack.
India’s biostatistics outsourcing market is set to grow 15 per cent in two years thanks to a 50 per cent cost saving compared with the West, according to a new survey.
ResearchNurses.co will conduct home visits in clinical trials for three Big Pharma firms after forging an agreement with Nottingham University Hospitals Research and Innovation Department.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
AstraZeneca and Assay Depot have launched a new “virtual research lab” which they say will allow a small group of scientists to run full drug discovery from a laptop.
BioFocus and Activiomics have teamed up to offer a drug discovery and biomarker service which it says will improve the identification of novel targets.
SPIC has pressed the Indian PM to issue a standardised excise duty to all contract manufacturers operating in the country so drugsmakers can have a level playing field.
BioFocus has taken on Titian’s sample management software in a bid to pump more resources into “refreshing” its 900,000 strong high-throughput screening (HTS) compound portfolio.
No job losses, facility divestitures or strategic changes are planned at DPT Laboratories according to new owner Renaissance Pharma, which bought the CDMO in an out-of-the-blue deal last week.
